NDAINTRAVENOUSSOLUTION
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
FLYRCADO (flurpiridaz f-18) by Bayer is positron emitting activity [moa]. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLYRCADO (flurpiridaz F-18) is a positron-emitting radioactive diagnostic agent administered intravenously as a solution. It is used for cardiac PET imaging to assess myocardial perfusion and detect coronary artery disease. The drug works via positron emission activity, enabling real-time visualization of cardiac blood flow and tissue viability.
Growth16.0 years to LOE
Recent approval positions FLYRCADO in growth phase with expanding cardiac imaging market adoption; commercial teams are actively building market presence with minimal competitive pressure.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLYRCADO at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.